|
ESPR | Esperion Therapeutics, Inc. |
|
|
ESPR | Esperion Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ -0.85 |
| Leverage | 224.90% |
| Market Cap | $ 512.6m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -103.8m |
| Margin | -38.17% |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.